FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018263752> ?p ?o ?g. }

• W2018263752 endingPage "1471" @default.
• W2018263752 startingPage "1459" @default.
• W2018263752 abstract "Although various mechanisms have been recognized as being associated with the development of resistance to imatinib mesylate in vitro and in clinical situations, their relative significance and contributions remain poorly understood, as is the sequence of events leading to the selection of the resistant phenotype. Experimental in vitro systems involving well defined cell lines and conditions can be used to some advantage to answer specific questions and to develop in vitro models of imatinib resistance that would reflect its potential heterogeneity.Two cell lines, KBM5 and KBM7, which expressed p210 Bcr/Abl and which differed in their inherent sensitivity to imatinib, the number of copies of the BCR/ABL fusion gene, and the activation of apoptotic pathways, were grown in vitro in the presence of increasing concentrations of imatinib. The resistant cells were analyzed for cell cycle progression, apoptotic response after exposure to imatinib, expression of Bcr/Abl, tyrosine kinase activity, and the presence of mutations within the adenosine triphosphate (ATP) coding domain of BCR/ABL. At various levels of resistance, the cells were transferred into drug-free media, and the stability of the resistant phenotype was determined in the absence of the drug.In KBM7 cells, the development of resistance was characterized by loss of apoptotic response to the drug, amplification of BCR/ABL, increased levels of expression of p210 Bcr/Abl, and decreased inhibition of Bcr/Abl tyrosine kinase (TK) activity by imatinib. No mutations within the ATP-binding domain of Bcr/Abl were identified, and resistance remained stable in the absence of the drug. In KBM5 cells, which previously were found to be characterized by the acquisition of a single C-T mutation at ABL nucleotide 944 (T315I) at high levels of resistance, this same mutation was detected at an intermediate level, but not at a low level, of resistance. The response of KBM5 cells to imatinib was characterized by a low level of apoptotic response, a marginal increase in BCR/ABL copy number, a modest increase in p210 expression, and a highly imatinib-resistant Bcr/Abl TK. Partial reversal of resistance was observed in highly resistant KBM5-STI571(R1.0) cells, which continued to display the C-T mutation. In KBM5 cells with an intermediate level of resistance, the T315I mutation was no longer detectable upon their reversal to the sensitive phenotype.BCR/ABL amplification with subsequent overexpression of Bcr/Abl protein, loss of apoptotic response, or point mutation of the ATP-binding site of BCR/ABL was associated alternatively with the acquisition of the resistant phenotype, supporting the notion that multiple mechanisms are involved in the induction of resistance to imatinib. The initial number of BCR/ABL copies itself was not related directly to the degree of resistance. The reversibility of the resistance may be complete, partial, or irreversible, depending on the mechanism(s) involved and the degree of resistance. Both cell lines serve as models for further elucidation of various aspects of imatinib-resistance mechanisms." @default.
• W2018263752 created "2016-06-24" @default.
• W2018263752 creator A5001480123 @default.
• W2018263752 creator A5004888325 @default.
• W2018263752 creator A5012295740 @default.
• W2018263752 creator A5030171128 @default.
• W2018263752 creator A5030706737 @default.
• W2018263752 creator A5055334005 @default.
• W2018263752 creator A5060552661 @default.
• W2018263752 creator A5080534438 @default.
• W2018263752 creator A5080815829 @default.
• W2018263752 creator A5085521139 @default.
• W2018263752 creator A5089428686 @default.
• W2018263752 creator A5090435894 @default.
• W2018263752 date "2004-01-01" @default.
• W2018263752 modified "2023-10-17" @default.
• W2018263752 title "Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein" @default.
• W2018263752 cites W120419820 @default.
• W2018263752 cites W120676909 @default.
• W2018263752 cites W1490418776 @default.
• W2018263752 cites W1964306758 @default.
• W2018263752 cites W1965295262 @default.
• W2018263752 cites W1968022845 @default.
• W2018263752 cites W1968071128 @default.
• W2018263752 cites W1973562717 @default.
• W2018263752 cites W1975431288 @default.
• W2018263752 cites W1985238075 @default.
• W2018263752 cites W1998593414 @default.
• W2018263752 cites W1999614615 @default.
• W2018263752 cites W2011474502 @default.
• W2018263752 cites W2016086822 @default.
• W2018263752 cites W2026389791 @default.
• W2018263752 cites W2038701282 @default.
• W2018263752 cites W2046933315 @default.
• W2018263752 cites W2048434111 @default.
• W2018263752 cites W2069153761 @default.
• W2018263752 cites W2069201630 @default.
• W2018263752 cites W2074740152 @default.
• W2018263752 cites W2079446921 @default.
• W2018263752 cites W2088594243 @default.
• W2018263752 cites W2090017206 @default.
• W2018263752 cites W2101390452 @default.
• W2018263752 cites W2105214030 @default.
• W2018263752 cites W2106602239 @default.
• W2018263752 cites W2142969636 @default.
• W2018263752 cites W2171722798 @default.
• W2018263752 cites W2263837564 @default.
• W2018263752 cites W2312804644 @default.
• W2018263752 cites W2329648702 @default.
• W2018263752 cites W2331087852 @default.
• W2018263752 cites W4241530587 @default.
• W2018263752 doi "https://doi.org/10.1002/cncr.20131" @default.
• W2018263752 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15042680" @default.
• W2018263752 hasPublicationYear "2004" @default.
• W2018263752 type Work @default.
• W2018263752 sameAs 2018263752 @default.
• W2018263752 citedByCount "41" @default.
• W2018263752 countsByYear W20182637522013 @default.
• W2018263752 countsByYear W20182637522014 @default.
• W2018263752 countsByYear W20182637522015 @default.
• W2018263752 countsByYear W20182637522016 @default.
• W2018263752 countsByYear W20182637522017 @default.
• W2018263752 countsByYear W20182637522018 @default.
• W2018263752 countsByYear W20182637522022 @default.
• W2018263752 countsByYear W20182637522023 @default.
• W2018263752 crossrefType "journal-article" @default.
• W2018263752 hasAuthorship W2018263752A5001480123 @default.
• W2018263752 hasAuthorship W2018263752A5004888325 @default.
• W2018263752 hasAuthorship W2018263752A5012295740 @default.
• W2018263752 hasAuthorship W2018263752A5030171128 @default.
• W2018263752 hasAuthorship W2018263752A5030706737 @default.
• W2018263752 hasAuthorship W2018263752A5055334005 @default.
• W2018263752 hasAuthorship W2018263752A5060552661 @default.
• W2018263752 hasAuthorship W2018263752A5080534438 @default.
• W2018263752 hasAuthorship W2018263752A5080815829 @default.
• W2018263752 hasAuthorship W2018263752A5085521139 @default.
• W2018263752 hasAuthorship W2018263752A5089428686 @default.
• W2018263752 hasAuthorship W2018263752A5090435894 @default.
• W2018263752 hasBestOaLocation W20182637521 @default.
• W2018263752 hasConcept C104317684 @default.
• W2018263752 hasConcept C125418893 @default.
• W2018263752 hasConcept C138626823 @default.
• W2018263752 hasConcept C170493617 @default.
• W2018263752 hasConcept C171122931 @default.
• W2018263752 hasConcept C190283241 @default.
• W2018263752 hasConcept C2777583451 @default.
• W2018263752 hasConcept C2778729363 @default.
• W2018263752 hasConcept C2778904597 @default.
• W2018263752 hasConcept C3019892230 @default.
• W2018263752 hasConcept C42362537 @default.
• W2018263752 hasConcept C43907098 @default.
• W2018263752 hasConcept C502942594 @default.
• W2018263752 hasConcept C54355233 @default.
• W2018263752 hasConcept C62112901 @default.
• W2018263752 hasConcept C62478195 @default.
• W2018263752 hasConcept C81885089 @default.
• W2018263752 hasConcept C86803240 @default.
• W2018263752 hasConcept C95444343 @default.

• next